Sign Up Today and Learn More About Engrail Therapeutics Stock
Invest in or calculate the value of your shares in Engrail Therapeutics or other pre-IPO companies through EquityZen's platform.
Engrail Therapeutics Stock (ENGT)
Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.
About Engrail Therapeutics Stock
Founded
2019
Headquarters
San Diego, CA, US
Industries
Messaging and Telecommunications, Content and Publishing, Sports
Engrail Therapeutics Press Mentions
Stay in the know about the latest news on Engrail Therapeutics
Gabaa receptor modulators and uses thereof
patents • Apr 02, 2025
GABAa RECEPTOR MODULATOR SALTS, PARTICLES, AND USES THEREOF
patents • Apr 02, 2025
Dopamine Receptor Antagonists Clinical Trial Pipeline Analysis: 10+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight
globenewswire • Mar 04, 2025
Gabaa receptor modulators and uses thereof
patents • Feb 07, 2025
Engrail Therapeutics reports compounds for treatment of depression, schizophrenia
bioworld • Jan 31, 2025
Engrail Therapeutics Management
Leadership team at Engrail Therapeutics
Board Member
Jasper Bos
Co-Founder ,Executive VP & Chief Development Officer
Stephen Cunningham
Join now and verify your accreditation status to gain access to:
- Engrail Therapeutics Current Valuation
- Engrail Therapeutics Stock Price
- Engrail Therapeutics Management
- Available deals in Engrail Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Engrail Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Engrail Therapeutics Revenue and Financials
- Engrail Therapeutics Highlights
- Engrail Therapeutics Business Model
- Engrail Therapeutics Risk Factors
- Engrail Therapeutics Research Report from SACRA Research
Trading Engrail Therapeutics Stock
How to invest in Engrail Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Engrail Therapeutics through EquityZen funds. These investments are made available by existing Engrail Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Engrail Therapeutics stock?
Shareholders can sell their Engrail Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
